Literature-reported formulation composition
Component: CL4F8-6 | mol%: 50 | Role: Ionizable lipid
sales@dcchemicals.com
CL4F8-6
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported formulation composition
Component: Cholesterol | mol%: 38.5 | Role: Sterol
Literature-reported formulation composition
Component: DSPC | mol%: 10 | Role: Helper phospholipid
Literature-reported formulation composition
Component: DMG-PEG2000 | mol%: 1.5 | Role: PEG lipid
Literature-reported formulation composition
Component: Reported total | mol%: 100 | Role: Source values retained
Table 3
Experiment: Particle characterization | Condition: Fresh formulation | Reported result: 88.78 nm; PDI 0.022; EE 99.4%; pKa 6.14
Table 3
Experiment: Reporter mRNA | Condition: 0.1 mg/kg IV; liver at 6 h | Reported result: Highest expression in the branched-lipid library
Table 3
Experiment: CRISPR editing | Condition: 2.5 mg/kg total RNA IV; day 30 | Reported result: 54% liver editing; 77% serum TTR reduction
Table 3
Experiment: Storage | Condition: 4 C; six months | Reported result: Particle size and EE unchanged versus initial in the reported study
Reported observation
Literature-reported Particle properties 88.78 nm; PDI 0.022; EE 99.4%; pKa 6.14 Fresh CL4F8-6 LNP SI Table S1
Reported observation
Literature-reported Liver Fluc expression Highest among the tested branched-lipid library 0.1 mg/kg Fluc mRNA IV; 6 h Primary article Fig. 5
Reported observation
Literature-reported Serum TTR reduction 77% 2.5 mg/kg total RNA IV; Cas9 mRNA:sgTTR = 1:2 w/w · Day 30 Primary article Fig. 6
Reported observation
Literature-reported Liver editing 54% 2.5 mg/kg total RNA IV · Day 30 Primary article Fig. 6
Reported observation
Literature-reported Spleen editing Not detected sgTTR and sgGFP control groups; n=3 SI Fig. S8
Reported observation
Hepatocyte expression EGFP microscopy showed expression mainly in hepatocytes after IV dosing. 0.5 or 1.5 mg/kg EGFP mRNA; 24 h · Primary article and SI imaging
Reported observation
Six-month storage CL4F8-6 LNP particle size and encapsulation efficiency were reported unchanged after six months at 4 C. Study formulation · Primary article and SI Fig. S5a-c